

**CURRENT LISTING OF PENDING CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application.

The listing is based on the last entered amendment of October 31, 2003:

1. (Currently Amended) A pharmaceutical composition for application at a biodegradable plate-containing site requiring new bone[,] or cartilage ~~or connective tissue~~ formation in a subject, comprising a plurality of bone marrow stromal cells (MSCs) and a pharmaceutically acceptable polymer, wherein the MSCs are isolated from the subject; are transduced *in vitro* after isolation from the subject with ~~wherein the MSCs comprise a replication-deficient viral~~ vector comprising a DNA sequence encoding BMP-2 operably linked to a promoter, and are applied at the biodegradable plate-containing site and a pharmaceutically acceptable polymer.

2. (Original) The composition as recited in Claim 1 wherein the polymer is selected from a group consisting of alginate and collagen.

3. (Original) The composition as recited in Claim 1 wherein the MSCs are present in a concentration of about  $50 \times 10^6$  per ml of the polymer.

4. (Previously Amended) The composition as recited in Claim 1 wherein the polymer is collagen type I.

5. (Currently Amended) A method of enhancing new bone[,] or cartilage ~~or connective tissue~~ formation in a subject, comprising:

- a. obtaining a plurality of bone marrow stromal cells (MSCs) from a the subject;
- b. transducing the MSCs of step a) with a replication-deficient viral vector comprising a DNA sequence encoding BMP-2 operably linked to a promoter to generate BMP-2 protein producing MSCs;
- c. applying a biodegradable plate to a site requiring new bone[,] or cartilage ~~or connective tissue~~ formation on the subject; and
- d. applying a composition comprising the BMP-2 protein producing MSCs and a pharmaceutically acceptable polymer to the site,

such that new bone[,] or cartilage ~~or connective tissue~~ formation is enhanced.

6. (Currently Amended) The method as recited in Claim 5 wherein the ~~DNA sequence encoding BMP-2 is transferred via~~ replication-deficient viral vector is an adenovirus.

7. (Cancelled)

8. (Previously Amended) The method as recited in Claim 5 wherein the protein producing MSCs are topically applied in a concentration of about  $50 \times 10^6$  per ml of a pharmaceutically acceptable polymer and produce an effective amount of the protein.

9. (Cancelled)

10. (Cancelled)

In re Chang  
Appln. No. 09/837,217  
Response of March 4, 2005

11. (Previously added) The composition of claim 1 wherein the composition is a gel.
12. (Previously added) The method of claim 5 wherein the composition is a gel.
13. (Previously added) The composition of claim 1 wherein the biodegradable plate comprises poly(lactic acid) (PLLA).
14. (Previously added) The method of claim 5 wherein the biodegradable plate comprises poly(lactic acid) (PLLA).